Brendan P. Eckelman - 22 May 2024 Form 4 Insider Report for Inhibrx, Inc. (INBX)

Role
Chief Scientific Officer
Signature
/s/ Kelly D. Deck, as attorney in fact for Brendan P. Eckelman
Issuer symbol
INBX
Transactions as of
22 May 2024
Transactions value $
-$170,941
Form type
4
Filing time
24 May 2024, 18:15:17 UTC
Previous filing
15 Mar 2024
Next filing
24 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INBX Stock Option (right to buy) Options Exercise -$85.6K -2.51K -27.35% $34.12 6.67K 22 May 2024 Common Stock 2.51K $33.63 Direct F1
transaction INBX Stock Option (right to buy) Options Exercise -$85.3K -2.5K -8.57% $34.12 26.7K 22 May 2024 Common Stock 2.5K $23.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
F2 Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.